{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:23:10Z","timestamp":1772119390757,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T00:00:00Z","timestamp":1424995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s10157-015-1101-7","type":"journal-article","created":{"date-parts":[[2015,2,25]],"date-time":"2015-02-25T22:21:13Z","timestamp":1424902873000},"page":"1199-1205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD)"],"prefix":"10.1007","volume":"19","author":[{"given":"Akiko","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruna","family":"Kawano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Horie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Muto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,27]]},"reference":[{"key":"1101_CR1","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369:1287\u2013301.","journal-title":"Lancet"},{"key":"1101_CR2","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10157-012-0741-0","volume":"17","author":"T Mochizuki","year":"2013","unstructured":"Mochizuki T, Tsuchiya K, Nitta K. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. Clin Exp Nephrol. 2013;17:317\u201326.","journal-title":"Clin Exp Nephrol"},{"key":"1101_CR3","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1172\/JCI107423","volume":"52","author":"GL Robertson","year":"1973","unstructured":"Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest. 1973;52:2340\u201352.","journal-title":"J Clin Invest"},{"key":"1101_CR4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/clinchem\/45.1.98","volume":"45","author":"M Kluge","year":"1999","unstructured":"Kluge M, Riedl S, Erhart-Hofmann B, Hartmann J, Waldhauser F. Improved extraction procedure and RIA for determination of arginine8-vasopressin in plasma: role of premeasurement sample treatment and reference values in children. Clin Chem. 1999;45:98\u2013103.","journal-title":"Clin Chem"},{"key":"1101_CR5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1023\/A:1022564803093","volume":"18","author":"FM Bree de","year":"1998","unstructured":"de Bree FM, Burbach JP. Structure-function relationships of the vasopressin prohormone domains. Cell Mol Neurobiol. 1998;18:173\u201391.","journal-title":"Cell Mol Neurobiol"},{"key":"1101_CR6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1373\/clinchem.2005.060038","volume":"52","author":"NG Morgenthaler","year":"2006","unstructured":"Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52:112\u20139.","journal-title":"Clin Chem"},{"key":"1101_CR7","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tem.2007.11.001","volume":"19","author":"NG Morgenthaler","year":"2008","unstructured":"Morgenthaler NG, Struck J, Jochberger S, Dunser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab. 2008;19:43\u20139.","journal-title":"Trends Endocrinol Metab"},{"key":"1101_CR8","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1210\/jc.2007-0232","volume":"92","author":"G Szinnai","year":"2007","unstructured":"Szinnai G, Morgenthaler NG, Berneis K, Struck J, M\u00fcller B, Keller U, et al. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab. 2007;92:3973\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1101_CR9","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1210\/jc.2014-2295","volume":"99","author":"R Roussel","year":"2014","unstructured":"Roussel R, Fezeu L, Marre M, Velho G, Fumeron F, Jungers P, et al. Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease. J Clin Endocrinol Metab. 2014;99(12):4656\u201363.","journal-title":"J Clin Endocrinol Metab."},{"key":"1101_CR10","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2012.08.038","volume":"61","author":"WE Boertien","year":"2013","unstructured":"Boertien WE, Meijer E, Li J, Bost JE, Struck J, Flessner MF, et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis. 2013;61:420\u20139.","journal-title":"Am J Kidney Dis"},{"key":"1101_CR11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.04560510","volume":"6","author":"E Meijer","year":"2010","unstructured":"Meijer E, Bakker SJ, van der Jagt EJ, Navis G, de Jong PE, Struck J, et al. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2010;6:361\u20138.","journal-title":"Clin J Am Soc Nephrol."},{"key":"1101_CR12","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1093\/ndt\/gfs070","volume":"27","author":"WE Boertien","year":"2012","unstructured":"Boertien WE, Meijer E, Zittema D, van Dijk MA, Rabelink TJ, Breuning MH, et al. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2012;27:4131\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"1101_CR13","first-page":"1533","volume":"9","author":"D Zittema","year":"2014","unstructured":"Zittema D, Berg EV, Meijer E, Boertien WE, Muller Kobold AC, Franssen CFM, et al. kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients. Clin J Am Soc Nephol. 2014;9:1533\u201362.","journal-title":"Clin J Am Soc Nephol."},{"key":"1101_CR14","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","volume":"343","author":"D Ravine","year":"1994","unstructured":"Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM. Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet. 1994;343:824\u20137.","journal-title":"Lancet"},{"key":"1101_CR15","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"1101_CR16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10157-011-0428-y","volume":"15","author":"S Tokiwa","year":"2011","unstructured":"Tokiwa S, Muto S, China T, Horie S. The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2011;15:539\u201345.","journal-title":"Clin Exp Nephrol."},{"key":"1101_CR17","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2215\/CJN.04180609","volume":"5","author":"I Barash","year":"2010","unstructured":"Barash I, Ponda MP, Goldfarb DS, Skolnik EY. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2010;5:693\u20137.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1101_CR18","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2215\/CJN.11311111","volume":"7","author":"D Zittema","year":"2012","unstructured":"Zittema D, Boertien WE, van Beek AP, Dullaart RP, Franssen CF, de Jong PE, et al. Vasopressin, copeptin and renal concentrating capacity in ADPKD patients without renal impairment. Clin J Am Soc Nephrol. 2012;7:906\u201313.","journal-title":"Clin J Am Soc Nephrol."},{"key":"1101_CR19","unstructured":"R Development Core Team. R. a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2011."},{"key":"1101_CR20","doi-asserted-by":"crossref","first-page":"F917","DOI":"10.1152\/ajprenal.00616.2011","volume":"302","author":"CC Graffe","year":"2012","unstructured":"Graffe CC, Bech JN, Lauridsen TG, Pedersen EB. Urinary excretion of AQP2 and ENaC in autosomal dominant polycystic kidney disease during basal conditions and after a hypertonic saline infusion. Am J Physiol Renal Physiol. 2012;302:F917\u201327.","journal-title":"Am J Physiol Renal Physiol."},{"key":"1101_CR21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ki.2009.397","volume":"77","author":"E Meijer","year":"2010","unstructured":"Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int. 2010;77:29\u201336.","journal-title":"Kidney Int"},{"key":"1101_CR22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1042\/CS20080140","volume":"116","author":"SS Bhandari","year":"2009","unstructured":"Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond). 2009;116:257\u201363.","journal-title":"Clin Sci (Lond)"},{"key":"1101_CR23","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.transproceed.2010.03.138","volume":"42","author":"P Przybylowski","year":"2010","unstructured":"Przybylowski P, Malyszko J, Malyszko JS. Copeptin in heart transplant recipients depends on kidney function and intraventricular septal thickness. Transplant Proc. 2010;42:1808\u201311.","journal-title":"Transplant Proc"},{"key":"1101_CR24","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1681\/ASN.2006090956","volume":"18","author":"D Fliser","year":"2007","unstructured":"Fliser D, Novak J, Thongboonkerd V, Argiles A, Jankowski V, Girolami MA, et al. Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol. 2007;18:1057\u201371.","journal-title":"J Am Soc Nephrol"},{"key":"1101_CR25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","volume":"7","author":"AB Chapman","year":"2012","unstructured":"Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, et al. kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012;7:479\u201386.","journal-title":"Clin J Am Soc Nephrol."},{"key":"1101_CR26","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.2215\/CJN.00360110","volume":"5","author":"E Meijer","year":"2010","unstructured":"Meijer E, Rook M, Tent H, Navis G, van der Jagt EJ, de Jong PE, et al. Early renal abnormalities in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2010;5:1091\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1101_CR27","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1681\/ASN.V491654","volume":"4","author":"GM Fick","year":"1994","unstructured":"Fick GM, Duley IT, Johnson AM, Strain JD, Manco-Johnson ML, Gabow PA. The spectrum of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol. 1994;4:1654\u201360.","journal-title":"J Am Soc Nephrol"},{"key":"1101_CR28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/TP.0b013e3181b11ae4","volume":"88","author":"E Meijer","year":"2009","unstructured":"Meijer E, Bakker SJ, de Jong PE, Homan van der Heide JJ, van Son WJ, Struck J, et al. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation. 2009;88:561\u20137.","journal-title":"Transplantation"},{"key":"1101_CR29","doi-asserted-by":"crossref","first-page":"R818","DOI":"10.1152\/ajpregu.00082.2013","volume":"304","author":"NK Littlejohn","year":"2013","unstructured":"Littlejohn NK, Siel RB Jr, Ketsawatsomkron P, Pelham CJ, Pearson NA, Hilzendeger AM, et al. Hypertension in mice with transgenic activation of the brain renin-angiotensin system is vasopressin dependent. Am J Physiol Regul Integr Comp Physiol. 2013;304:R818\u201328.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"1101_CR30","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1161\/HYPERTENSIONAHA.111.00356","volume":"61","author":"AM Hilzendeger","year":"2013","unstructured":"Hilzendeger AM, Cassell MD, Davis DR, Stauss HM, Mark AL, Grobe JL, et al. Angiotensin type 1a receptors in the subfornical organ are required for deoxycorticosterone acetate-salt hypertension. Hypertension. 2013;61:716\u201322.","journal-title":"Hypertension"},{"key":"1101_CR31","doi-asserted-by":"crossref","first-page":"e5301","DOI":"10.1371\/annotation\/9281c713-d253-4a1a-8255-92e691e77a24","volume":"8","author":"AD Kistler","year":"2013","unstructured":"Kistler AD, Serra AL, Siwy J, Poster D, Krauer F, Torres VE, et al. urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS one. 2013;8:e5301.","journal-title":"PLoS one"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-015-1101-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10157-015-1101-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-015-1101-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T16:20:22Z","timestamp":1651335622000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10157-015-1101-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,27]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1101"],"URL":"https:\/\/doi.org\/10.1007\/s10157-015-1101-7","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725379392.793537897","asserted-by":"object"}]},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,27]]}}}